Document Detail

Moxonidine improves cardiac structure and performance in SHR through inhibition of cytokines, p38 MAPK and Akt.
MedLine Citation:
PMID:  21426316     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND PURPOSE: Regression of left ventricular hypertrophy by moxonidine, a centrally acting sympatholytic imidazoline compound, results from a sustained reduction of DNA synthesis and transient stimulation of DNA fragmentation. Because apoptosis of cardiomyocytes may lead to contractile dysfunction, we investigated in spontaneously hypertensive rats (SHR), time- and dose-dependent effects of in vivo moxonidine treatment on cardiac structure and function as well as on the inflammatory process and signalling proteins involved in cardiac cell survival/death.
EXPERIMENTAL APPROACH: 12 week old SHR received moxonidine at 0, 100 and 400 µg·kg(-1)·h(-1) , s.c., for 1 and 4 weeks. Cardiac function was evaluated by echocardiography; plasma cytokines were measured by elisa and hearts were collected for histological assessment of fibrosis and measurement of cardiac proteins by Western blotting. Direct effects of moxonidine on cardiac cell death and underlying mechanisms were investigated in vitro by flow cytometry and Western blotting.
KEY RESULTS: After 4 weeks, the sub-hypotensive dose of moxonidine (100 µg) reduced heart rate and improved global cardiac performance, reduced collagen deposition, regressed left ventricular hypertrophy, inhibited Akt and p38 MAPK phosphorylation, and attenuated circulating and cardiac cytokines. The 400 µg dose resulted in similar effects but of a greater magnitude, associated with blood pressure reduction. In vitro, moxonidine inhibited norepinephrine-induced neonatal cardiomyocyte mortality but increased fibroblast mortality, through I(1)-receptor activation and differential effects on downstream Akt and p38 MAPK.
CONCLUSIONS AND IMPLICATIONS: While the antihypertensive action of centrally acting imidazoline compounds is appreciated, new cardiac-selective I(1)-receptor agonists may confer additional benefit.
H Aceros; G Farah; L Cobos-Puc; A M Stabile; N Noiseux; S Mukaddam-Daher
Related Documents :
17016696 - Global myocardial perfusion and diastolic function are impaired to a similar extent in ...
16111916 - Anaemia and coronary artery disease severity in patients with heart failure.
17220816 - Poststress left ventricular ejection fraction is an independent predictor of major card...
15226626 - Relation of secretory phospholipase a(2) and high-sensitivity c-reactive protein to chl...
16877796 - Side-strut stenting technique for the treatment of aorto-ostial in-stent restenosis and...
9525556 - Evaluation of coronary flow velocity dynamics and flow reserve in patients with kawasak...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  British journal of pharmacology     Volume:  164     ISSN:  1476-5381     ISO Abbreviation:  Br. J. Pharmacol.     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-09-09     Completed Date:  2012-03-19     Revised Date:  2013-06-30    
Medline Journal Info:
Nlm Unique ID:  7502536     Medline TA:  Br J Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  946-57     Citation Subset:  IM    
Copyright Information:
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.
Centre Hospitalier de L'Université de Montréal Research Center, Québec, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / pharmacology*
Blood Pressure / drug effects
Cell Death / drug effects
Cell Survival / drug effects
Collagen / metabolism
Cytokines / antagonists & inhibitors*,  blood,  metabolism
Echocardiography / methods
Fibroblasts / drug effects,  metabolism,  physiology
Fibrosis / drug therapy,  metabolism
Heart / anatomy & histology,  drug effects*,  physiology
Heart Rate / drug effects
Hypertension / drug therapy,  physiopathology
Hypertrophy, Left Ventricular / drug therapy,  metabolism
Imidazoles / pharmacology*
Inflammation / drug therapy,  metabolism
Myocardium / enzymology
Myocytes, Cardiac / drug effects,  metabolism,  pathology
Phosphorylation / drug effects
Proto-Oncogene Proteins c-akt / antagonists & inhibitors*,  metabolism
Rats, Inbred SHR
Rats, Inbred WKY
p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors*,  metabolism
Grant Support
MOP-82708//Canadian Institutes of Health Research
Reg. No./Substance:
0/Antihypertensive Agents; 0/Cytokines; 0/Imidazoles; 75438-57-2/moxonidine; 9007-34-5/Collagen; EC Proteins c-akt; EC Mitogen-Activated Protein Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Protein kinase A and the exchange protein directly activated by cAMP (Epac) modulate phenotype plast...
Next Document:  Preserved arterial vasodilatation via endothelial protease-activated receptor-2 in obese type 2 diab...